- Home
- EU vs RNXT Comparison
EU vs RNXT Comparison
Compare EU & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EU
- RNXT
- Stock Information
- Founded
- EU 2009
- RNXT 2012
- Country
- EU United States
- RNXT United States
- Employees
- EU N/A
- RNXT N/A
- Industry
- EU Other Metals and Minerals
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- EU Basic Materials
- RNXT Health Care
- Exchange
- EU Nasdaq
- RNXT Nasdaq
- Market Cap
- EU N/A
- RNXT 37.6M
- IPO Year
- EU N/A
- RNXT 2021
- Fundamental
- Price
- EU $1.70
- RNXT $1.06
- Analyst Decision
- EU Strong Buy
- RNXT Strong Buy
- Analyst Count
- EU 2
- RNXT 2
- Target Price
- EU $4.38
- RNXT $7.00
- AVG Volume (30 Days)
- EU 1.9M
- RNXT 116.6K
- Earning Date
- EU 05-20-2025
- RNXT 05-15-2025
- Dividend Yield
- EU N/A
- RNXT N/A
- EPS Growth
- EU N/A
- RNXT N/A
- EPS
- EU N/A
- RNXT N/A
- Revenue
- EU $58,334,000.00
- RNXT $43,000.00
- Revenue This Year
- EU $27.46
- RNXT $4,755.81
- Revenue Next Year
- EU $140.12
- RNXT $187.93
- P/E Ratio
- EU N/A
- RNXT N/A
- Revenue Growth
- EU 163.38
- RNXT N/A
- 52 Week Low
- EU $1.01
- RNXT $0.75
- 52 Week High
- EU $4.97
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- EU 59.84
- RNXT 60.35
- Support Level
- EU $1.52
- RNXT $1.02
- Resistance Level
- EU $1.73
- RNXT $1.09
- Average True Range (ATR)
- EU 0.11
- RNXT 0.05
- MACD
- EU 0.04
- RNXT 0.01
- Stochastic Oscillator
- EU 93.33
- RNXT 80.00
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.